Advertisement

Topics

Basilea licenses late-stage oncology drug candidate derazantinib from ArQule

03:15 EDT 17 Apr 2018 | GlobalNewsWire (2014)

This article has expired, however you can still download the PDF.
Preview:
Basilea Pharmaceutica AG / Basilea licenses late-stage oncology drug candidate derazantinib from ArQule . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. Basel, S...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "Basilea licenses late-stage oncology drug candidate derazantinib from ArQule"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...